Trials / Withdrawn
WithdrawnNCT00092274
Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma
An Open-label, International, Multicenter, Dose Escalating, Phase I/II Study of HuMax-CD20 in Patients With Relapsed or Refractory Follicular Lymphoma Grade I-II
- Status
- Withdrawn
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to determine the safety and efficacy of HuMax-CD20 as a treatment for Follicular Lymphoma (FL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HuMax-CD20 |
Timeline
- Start date
- 2004-09-01
- Primary completion
- 2005-01-01
- Completion
- 2005-01-01
- First posted
- 2004-09-27
- Last updated
- 2015-04-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00092274. Inclusion in this directory is not an endorsement.